Orientbio Inc. (002630) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Orientbio Inc. (002630:KRX), powered by AI.

Current Price
₩547
P/E Ratio
-4.9
Market Cap
64.9B
Sector
Healthcare
What is the Orientbio Inc. stock price forecast?

Orientbio Inc. is currently trading at ₩547. View real-time AI analysis on Alpha Lenz.

What is Orientbio Inc. insider trading activity?

View the latest insider trading data for Orientbio Inc. on Alpha Lenz.

What is Orientbio Inc.'s P/E ratio?

Orientbio Inc.'s P/E ratio is -4.9.

Orientbio Inc.

KRX · 002630
₩547
Ask about Orientbio Inc.'s future dividend policy...
Alpha Chat Insight

Orientbio Inc. trades at a P/E of -4.9 (undervalued) with modest ROE of -16.8%.

Ask for details

Company Overview

Orientbio Inc. operates as a biotechnology company primarily engaged in the research, development, and commercialization of advanced biotechnological products and solutions. The company's core focus is on delivering cutting-edge innovations in life sciences, targeting diverse areas such as biomedical research, diagnostic applications, and therapeutic solutions. With its extensive expertise in genetic engineering and molecular biology, Orientbio Inc. plays a significant role in the pharmaceutical and healthcare industries by facilitating the development of essential medical breakthroughs. Furthermore, the company is involved in producing and supplying high-quality biological materials and services to research institutions and biopharma companies worldwide. Through its contributions, Orientbio Inc. is pivotal in advancing medical research, improving disease understanding, and supporting the creation of novel treatments. By harnessing the potentials of biotechnology, it remains an influential entity in the ongoing efforts to address global health challenges.

CEO장재진
SectorHealthcare
IndustryBiotechnology
0

Company Statistics

FY 2025

Profile

₩64,864,903,735Market Cap
₩29,397,883,040Revenue
118.58MShares Out
0Employees

Margins

24.48%Gross
2.22%EBITDA
-10.46%Operating
-44.88%Pre-Tax
-44.88%Net

Valuation

-4.92P/E
0.90P/B
2.21EV/Sales
93.50EV/EBITDA
-16.07P/FCF

Growth (CAGR)

3.81%Rev 3Yr
-4.61%Rev 5Yr
N/AOp Inc 3Yr
N/AOp Inc 5Yr
N/ANet Inc 3Yr
N/ANet Inc 5Yr

Returns

-14.52%ROA
-16.81%ROE
-14.28%ROIC

Financial Health

₩6,531,858,690Cash & Cash Equivalents
₩6,403,183,400Net Debt
18.00%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

Orientbio Inc. (ticker: 002630) is a company listed on KRX in the Healthcare sector (Biotechnology). Market cap is $64.9B.

The current price is ₩547 with a P/E ratio of -4.92x and P/B of 0.9x.

ROE is -16.81% and operating margin is -10.46%. Annual revenue is $29.4B.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
Orientbio Inc. (Healthcare) Stock Forecast & Analysis ₩547 | Alpha Lenz